Antibiotic Drugs

Tuberculosis, once thought to be a disease virtually eliminated in the first world has become a major health concern. Health care workers, the immunosuppressed, and HIV-positive people are particularly at risk. The rising rate of infection with M. tuberculosis along with the increase in antibiotic-resistant strains has made the development of new antibiotics for the treatment of tuberculosis of major importance for public health. Rifapentine (Priften, Hoechst Marion Roussel), a member of the rifamycin class of antibiotics, was approved in June, 1998 for the treatment of pulmonary tuberculosis.

Antibiotics are often an essential component of the therapeutic plan that is developed to improve the clinical course of a patient. Typically, certain antibiotics are better for a given clinical condition. Allergies to these antibiotics, however, may limit the use of these antibiotics and in certain cases may complicate the course of optimal care. Allergies to antibiotics have become an great hindrance to the clinician.

Carbapenem antibiotics were first discovered in the 1970s. The first and only marketed agent in this class was Primaxin, a combination product containing imipenem and the human renal dihyropeptidase-I (DHP-I) antagonist cilastatin.